Humacyte (NASDAQ:HUMA) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Humacyte (NASDAQ:HUMA) from a hold rating to a sell rating in a report released on Sunday.

Several other brokerages also recently issued reports on HUMA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Thursday, November 20th. BTIG Research reissued a “buy” rating and issued a $6.00 target price on shares of Humacyte in a report on Friday, November 21st. UBS Group restated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Finally, Barclays started coverage on Humacyte in a research report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price objective on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.29.

Humacyte Stock Performance

NASDAQ HUMA opened at $1.11 on Friday. Humacyte has a 12 month low of $1.06 and a 12 month high of $6.77. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The stock’s fifty day moving average price is $1.40 and its 200-day moving average price is $1.81. The stock has a market cap of $207.87 million, a P/E ratio of -4.83 and a beta of 1.90.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.92 million. As a group, equities analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. Heights Capital Management Inc. purchased a new stake in shares of Humacyte during the 1st quarter valued at about $6,863,000. RA Capital Management L.P. bought a new stake in Humacyte during the first quarter valued at approximately $5,648,000. Marshall Wace LLP increased its holdings in Humacyte by 5,308.2% during the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after buying an additional 2,590,394 shares during the last quarter. CenterBook Partners LP raised its position in Humacyte by 141.1% in the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock worth $7,169,000 after acquiring an additional 2,007,743 shares during the period. Finally, Woodline Partners LP boosted its stake in shares of Humacyte by 38.7% during the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock worth $6,735,000 after acquiring an additional 1,101,198 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.